Biocompatibility testing infographic for an implantable coronary stent

Biocompatibility Testing: The Invisible Safety Layer Behind Every Stent

Before a coronary stent ever reaches a cath lab, it has to pass one of the most rigorous testing regimes in medical device development: biocompatibility testing under ISO 10993, the international standard governing the biological evaluation of medical devices.

A coronary stent is classified as a permanent, blood-contacting implant. That classification alone triggers a demanding evaluation panel, because the device isn't just expected to work mechanically. It has to coexist safely with living tissue and circulating blood for the rest of a patient's life.

The seven-part evaluation

1. Cytotoxicity — Does the material damage or kill cells on contact?
2. Sensitization — Could the material trigger an allergic or immune hypersensitivity reaction?
3. Irritation — Does the device cause local tissue inflammation?
4. Hemocompatibility — Does it activate clotting, damage red blood cells, or trigger complement activation?
5. Genotoxicity — Could the material or its degradation products cause DNA damage?
6. Systemic toxicity — Could the device cause harm beyond the implant site?
7. Implantation study — How does surrounding tissue respond over extended implantation periods?

Why this matters beyond the checklist

Every material is evaluated, not just the finished assembly: the metal platform, any polymer coating, the therapeutic drug in a drug-eluting stent, and even manufacturing residues left behind after processing.

This is where quality systems and design verification intersect most directly with patient safety. A change as small as a new adhesive or coating supplier can trigger a re-evaluation of the biocompatibility file.

It's unglamorous work. It's also the reason a device this small can safely sit inside an artery for a patient's lifetime.